Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 23, 2005 | Published + Supplemental Material
Journal Article Open

GABA Transporter Deficiency Causes Tremor, Ataxia, Nervousness, and Increased GABA-Induced Tonic Conductance in Cerebellum

Abstract

GABA transporter subtype 1 (GAT1) knock-out (KO) mice display normal reproduction and life span but have reduced body weight (female, -10%; male, -20%) and higher body temperature fluctuations in the 0.2-1.5/h frequency range. Mouse GAT1 (mGAT1) KO mice exhibit motor disorders, including gait abnormality, constant 25-32 Hz tremor, which is aggravated by flunitrazepam, reduced rotarod performance, and reduced locomotor activity in the home cage. Open-field tests show delayed exploratory activity, reduced rearing, and reduced visits to the central area, with no change in the total distance traveled. The mGAT1 KO mice display no difference in acoustic startle response but exhibit a deficiency in prepulse inhibition. These open-field and prepulse inhibition results suggest that the mGAT1 KO mice display mild anxiety or nervousness. The compromised GABA uptake in mGAT1 KO mice results in an increased GABA_A receptor-mediated tonic conductance in both cerebellar granule and Purkinje cells. The reduced rate of GABA clearance from the synaptic cleft is probably responsible for the slower decay of spontaneous IPSCs in cerebellar granule cells. There is little or no compensatory change in other proteins or structures related to GABA transmission in the mGAT1 KO mice, including GAT1-independent GABA uptake, number of GABAergic interneurons, and GABA_A-, vesicular GABA transporter-, GAD65-, and GAT3-immunoreactive structures in cerebellum or hippocampus. Therefore, the excessive extracellular GABA present in mGAT1 KO mice results in behaviors that partially phenocopy the clinical side effects of tiagabine, suggesting that these side effects are inherent to a therapeutic strategy that targets the widely expressed GAT1 transporter system.

Additional Information

© 2005 Society for Neuroscience. Received Aug. 16, 2004; revised Jan. 25, 2005; accepted Jan. 25, 2005. This research was supported by National Institutes of Health Grants DA-01921, NS-11756, MH-49176, NS-030549, and DA-010509, National Science Foundation Grant 0119493, the Wellcome Trust, a Royal Society-Wolfson Award (S.C.-C.), and a Della Martin Fellowship (C.-S.C.). We are indebted to members of Caltech and University of California Los Angeles groups for advice, Limin Shi and Paul Patterson for use and help with the startle system, and J. Crawley for comments on this manuscript.

Attached Files

Published - 3234.full.pdf

Supplemental Material - Chiu-04-supplementary-figur.gif

Files

Chiu-04-supplementary-figur.gif
Files (835.7 kB)
Name Size Download all
md5:23601a31ed55d3fa2a79d63fc0685fac
160.9 kB Preview Download
md5:f5ae024c08dc18463d639154515a3e19
674.8 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 20, 2023